Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study. 15. Januar 2018 Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Goebell, 2017. Oncol Res Treat 40 (suppl 3)(P343), 97–98. German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany. Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017. Oncol Res Treat 40 (suppl 3)(P524), 139–140. Weiterlesen Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry. Goebell, P.J., Müller, L., Staehler, M., Müller, Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017. Oncol Res Treat 40 (suppl 3)(V420), 114. Weiterlesen